This company has been marked as potentially delisted and may not be actively trading. NASDAQ:XTLB XTL Biopharmaceuticals (XTLB) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisCompetitorsEarningsHeadlinesShort InterestTrendsBuy This Stock About XTL Biopharmaceuticals Stock (NASDAQ:XTLB) 30 days 90 days 365 days Advanced Chart Get XTL Biopharmaceuticals alerts:Sign Up Key Stats Today's Range$1.13▼$1.1350-Day Range$3.43▼$5.2052-Week Range$0.86▼$3.05VolumeN/AAverage Volume27,742 shsMarket Capitalization$7.47 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview XTL Biopharmaceuticals Ltd. engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases. Its pipeline includes hCDR1 and Erythropoietin. The company was founded on March 9, 1993 and is headquartered in Ramat Gan, Israel. Read More Receive XTLB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for XTL Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address XTLB Stock News HeadlinesXTL Biopharmaceuticals Approves Key Resolutions at Shareholder MeetingJuly 28, 2025 | tipranks.comXTL Biopharmaceuticals Stock (NASDAQ:XTLB), Insider Trading ActivityJuly 8, 2025 | benzinga.comChina's 500 Million Year AdvantageThe "Impossible" Chip That Runs on Pure Light Google's quantum computer shocked the world... but China DEMOLISHED Google's record using pure light particles instead of exotic superconductors. The secret? A revolutionary material that ONE American company is the first to commercially produce. | The Oxford Club (Ad)XTL Biopharmaceuticals Ltd. (XTLB) - Yahoo FinanceJune 30, 2025 | uk.finance.yahoo.comXTL Biopharmaceuticals names Noam Band as CEOApril 9, 2025 | uk.investing.comXTL Biopharmaceuticals Ltd.: XTL Names Mr. Noam Band as its New Chief Executive OfficerApril 8, 2025 | finanznachrichten.deXTL Biopharmaceuticals Appoints Noam Band as CEOApril 7, 2025 | tipranks.comXTL Names Mr. Noam Band as its New Chief Executive OfficerApril 7, 2025 | globenewswire.comSee More Headlines XTLB Stock Analysis - Frequently Asked Questions How were XTL Biopharmaceuticals' earnings last quarter? XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) announced its quarterly earnings results on Monday, December, 30th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter. When did XTL Biopharmaceuticals' stock split? XTL Biopharmaceuticals's stock reverse split on the morning of Friday, February 10th 2017.The 1-5 reverse split was announced on Wednesday, January 25th 2017. The number of shares owned by shareholders was adjusted after the market closes on Thursday, February 9th 2017. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. What other stocks do shareholders of XTL Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that XTL Biopharmaceuticals investors own include Regulus Therapeutics (RGLS), Akari Therapeutics (AKTX), Exelixis (EXEL), Gilead Sciences (GILD), Pfizer (PFE), Supernus Pharmaceuticals (SUPN) and Titan Pharmaceuticals (TTNP). Company Calendar Last Earnings12/30/2024Today8/10/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED-DRUGS Sub-IndustryN/A Current SymbolNASDAQ:XTLB CIK1023549 Webwww.xtlbio.com Phone(729) 955-7080Fax972-3611-6605EmployeesN/AYear FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio0.61 Quick Ratio0.61 Sales & Book Value Annual Sales$450 thousand Price / Sales16.59 Cash FlowN/A Price / Cash FlowN/A Book Value$1.00 per share Price / Book1.37Miscellaneous Outstanding Shares5,450,000Free Float3,869,000Market Cap$7.47 million OptionableNot Optionable Beta1.09 Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report This page (NASDAQ:XTLB) was last updated on 8/10/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredIs This Stock the 'Next Nvidia'?'AI Bottleneck' Now Threatens Entire Magnificent 7 A new critical failure has appeared in the AI market, an...Altimetry | SponsoredGreen Light for These StocksGuess Who Washington Will Partner With Next? The U.S. government just made a bold $400 million move... beco...Stansberry Research | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding XTL Biopharmaceuticals Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share XTL Biopharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free XTLB Stock Alerts